Efficacy and safety of intraspinal injection of neural stem cell on progression of amyotrophic lateral sclerosis (ALS)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201107221696N3

Enrollment

Registered

2011-08-21

Start date

2011-06-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic lateral sclerosis. Motor neuron disease

Interventions

Intraspinal injection of neural stem cell.

Treatment - Other

Intraspinal injection of neural stem cell

Eligibility

Sex/Gender

All

Age

25 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1. Definite, probable or laboratory supported probable ALS (El Escorial criteria) 2. age 25-70 yrs 3. disease progression for duration of more than 6 months and less than 36 months 4. EMG-NCV confirms the diagnosis 5. FVC more than 50% 6. INR less than 1.5 7. Platelet count more than 100000 Exclusion criteria: 1. Any major systemic or psychiatric illness 2. any coexisting neurodegenerative disease 3. No other major pathology in brain or spinal cord 4. history of hematologic or lymphoproliferative disease 5. history of stem cell treatment of any kind

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Disability. Timepoint: Six months. Method of measurement: ALSFRS-R.	—

Secondary

Measure	Time frame
Quality of life. Timepoint: Six months. Method of measurement: ALSAQ40.;Forced vital capacity. Timepoint: Six months. Method of measurement: Spirometry.;Electrophysiologic parameters. Timepoint: Six months. Method of measurement: EMG-NCV.;Muscle strength. Timepoint: Six months. Method of measurement: MRC.;Side effects. Timepoint: Six months. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Taher Taheri

Shafa Neuroscience research center

s_nafissi@yahoo.com+98 21 8888 4040

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026